Empowering Hospitals, Innovators, and Investors Across Every Sector
The DarrowEverett Health Care & Life Sciences Practice advises clients across the heavily regulated and consistently evolving health care and life sciences industry. Service providers including hospitals; facilities; manufacturers; suppliers; lenders; investors; academia; and healthcare technology, biotechnology, food and dietary supplement, insurance, medical device, and pharmaceutical companies turn to us for assistance with the myriad of legal and regulatory issues and challenges that they face day to day in their businesses.
The DE team has extensive experience in healthcare mergers, acquisitions, joint ventures; strategic positioning, restructuring, capital access, private equity investments, divestitures, and bankruptcies. We aid with licensing, tax issues, government investigations, employment matters, governance, regulatory compliance, and Medicare/Medicaid reimbursement disputes and have litigated complex disputes involving commercial transactions and allegations of fraud, anti-kickback, and false claims act violations.
Our clients that manufacture or market products regulated by the US Food and Drug Administration (FDA) must also deal with the constantly changing procedural, regulatory, and legislative matters surrounding compliance, enforcement and product development, approvals, launch, sales, and marketing, reporting obligations, disclosures, and recalls.
The DE Health Care Practice Group regularly advises clients on:
Contact Us to Ensure Compliance and Protect Your Business
Let us know how DarrowEverett can serve your organization.
DE Insights
Our team wants you to stay informed about legal and regulatory developments that impact your business.
Client Insight
The Business Value of Engaging a Litigator Before You Are In Court
The point when what began as a negotiation, or even a conversation, ripens into a full-blown lawsuit is rarely clear. Yet it is certainly clear that the courtroom is not where any of the parties to a once-promising business relationship wanted to land. Without careful management from the outset, myriad day-to-day business disagreements could expose…
Read moreClient Insight
The DOJ’s New White-Collar Agenda: Implications for Businesses
On May 12, 2025, the Department of Justice (the “DOJ”) released its criminal—and, more specifically, white collar crime enforcement—initiatives under the current administration. This is typical each time new leadership assumes control of the DOJ, and below is a summary of key changes clients should expect in the coming years. Although the Trump administration has…
Read moreClient Insight
AI Meets TCPA: Navigating Business Compliance Risks in Phone Communications
As artificial intelligence continues to transform business communications, companies will continue to face significant—and in some cases, increased—legal risks under the Telephone Consumer Protection Act (TCPA) when choosing to utilize AI-powered calling and messaging technologies. The Federal Communications Commission’s (FCC) recent regulatory actions in the past year confirm that AI-powered tools are not exempt from…
Read more